Next Generation News and Research

RSS

MindFrame receives CE mark approval for Capture LP and Flow LP devices

MindFrame Inc. today announces receiving CE mark approval for the MindFrame Capture LP™ and MindFrame Flow LP™ devices. Part of the comprehensive portfolio of MindFrame Therapy Solutions™, these low profile devices can be deployed through a smaller microcatheter to improve access through tortuous vessel anatomies.

2 Aug 2011

Nature Biotechnology publishes BGI, GT Life Sciences' study on CHO K1 genome

BGI, the world's largest genomics organization, and GT Life Sciences, Inc., a privately held biotechnology company that utilizes a proven metabolic modeling and experimental platform to drive the discovery and design of new products and processes for the life sciences field, announced today that their collaborative study on the genomic sequence of the Chinese hamster ovary (CHO) K1 cell line was published July 31, 2011 online in Nature Biotechnology.

1 Aug 2011

Electrochem launches new company website and corporate brand

Electrochem Solutions, Inc. announced today the launch of its rebranded and redesigned company website.

1 Aug 2011

Skin cancer vaccine on the way: Cancer expert Prof Ian Frazer

In a major medical breakthrough, cancer expert Prof Ian Frazer is on the verge of developing a vaccine against skin cancer within a year. The former ‘Australian of the Year’ and creator of the world's first cervical cancer vaccine, Gardasil, has developed a world-first strategy to combat the insidious disease that affects two out of three Australians.

31 Jul 2011

CDC, ZKBS classifies Advaxis Agents as non-pathogenic materials

Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, has received affirmation by the Public Health Service of the U. S. Centers for Disease Control and Prevention and the Zentrale Kommission für die Biologische Sicherheit, the Central Commission for Biological Safety in Germany, that Advaxis strains, constructs and immunotherapies have been attenuated to the point that they are classified as non-pathogenic materials for handling and shipment.

30 Jul 2011

POSI first in the U.S. to provide Genium Bionic Prosthetic System for patients

Prosthetic Orthotic Solutions International (POSI), a Physiotherapy Associates company with locations in Marlton, NJ and Horsham, PA, announces it is one of the first clinics in the U.S. to fit patients with Otto Bock Healthcare's Genium Bionic Prosthetic System, and the first facility in the NJ/PA metro area to fit patients with this system.

30 Jul 2011

Curis second quarter net loss increases to $4.9 million

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today reported its financial results for the second quarter ended June 30, 2011.

28 Jul 2011

Mitochondrial genome undergoes random reorganisation during reprogramming

Induced pluripotent stem cells (iPS cells) are truly talented multi-taskers. They can reproduce almost all cell types and thus offer great hope in the fight against diseases like Alzheimer's and Parkinson's. However, it would appear that their use is not entirely without risk: during the reprogramming of body cells into iPS cells, disease-causing mutations can creep into the genetic material.

28 Jul 2011

Noninvasive brain computer interface could turn thoughts into motion

"Brain cap" technology being developed at the University of Maryland allows users to turn their thoughts into motion. Associate Professor of Kinesiology José 'Pepe' L. Contreras-Vidal and his team have created a non-invasive, sensor-lined cap with neural interface software that soon could be used to control computers, robotic prosthetic limbs, motorized wheelchairs and even digital avatars.

28 Jul 2011

University of Pittsburgh to honor Synthetic Genomics CEO with Dickson Prize

The scientist-entrepreneur who led efforts to map the first draft of the human genome as well as the complete diploid genome and to construct the first synthetic bacterium has been named this year's recipient of the University of Pittsburgh's Dickson Prize in Medicine.

28 Jul 2011

Viewpoints: Chambliss on reviving Gang of Six proposal; WSJ on Medicare Part D; Friedman on 'doing this right'

I joined five other senators to identify the difficult issues and make the hard, necessary decisions to address the twin challenges of our deficit and debt. ... Among other provisions, our proposal reduces the debt by $3.7 trillion over the next 10 years, stabilizes our publicly held debt by 2014, and imposes tough and honest budget enforcement.

28 Jul 2011

Epitomics launches 23 novel cancer-related antibodies

Epitomics, Inc., a biotechnology company commercializing the next generation of antibodies based on its groundbreaking Rabbit Monoclonal technology, today announced the Company has now launched 23 novel cancer-related antibodies that were developed through a partnership with the National Cancer Institute's Center for Cancer Research.

27 Jul 2011

Corning second quarter sales increase 17% to $2 billion

Corning Incorporated today announced its results for the second quarter of 2011.

27 Jul 2011

GCMS, PBS Biotech sign distribution agreement for single-use bioreactors in Korea

PBS Biotech, Inc., a developer of state of the art single-use bioreactors for the fast growing biotechnology market, announced today it has signed an exclusive distribution agreement in Korea with Green Cross Medical Sciences Corp. (GCMS), a division of Green Cross Corporation, one of Korea's largest pharmaceutical firms.

26 Jul 2011

Advaxis submits protocol revision for ADXS-HPV CIN Phase II study

Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, has submitted a protocol revision that has passed FDA review for the enrollment of the next 40 subject "mid strength" dose cohort in the dose-ranging Phase II study of ADXS-HPV, an immunotherapy for Cervical Intraepithelial Neoplasia.

26 Jul 2011

Resolute drug-eluting stent superior to Taxus DES for coronary artery disease

The Resolute drug-eluting stent (DES) from Medtronic, Inc., showed superiority to Boston Scientific Corp.'s Taxus DES on the primary endpoint of the RESOLUTE Japan clinical study: in-stent late lumen loss at eight months.

26 Jul 2011

Accelr8 and Novartis extend collaboration for BACcel system development

Accelr8 Technology Corporation announced that Accelr8 and Novartis have extended their program agreement through September 30, 2011. Having reviewed new data, Novartis will now install a system in their own facility to expand development capacity.

25 Jul 2011

LAUNCH program focuses on sustainable energy challenges

The U.S. Agency for International Development (USAID), NASA, the U.S. Department of State, and NIKE, Inc. have partnered on a unique initiative called LAUNCH. The LAUNCH: Energy Challenge, announced today, formally begins the third module of the LAUNCH program which is focused on sustainable energy challenges for the developed and developing worlds.

25 Jul 2011